Title:A Clinical Perspective of Soluble Epoxide Hydrolase Inhibitors in
Metabolic and Related Cardiovascular Diseases
Volume: 15
Author(s): Kanika Verma, Smita Jain, Swati Paliwal, Sarvesh Paliwal and Swapnil Sharma*
Affiliation:
- Department of Pharmacy, Banasthali Vidyapith Banasthali, P.O. Rajasthan 304022, India
Keywords:
Soluble epoxide hydrolase, arachidonic acid, metabolic syndrome, hypertension, diabetes, clinical, cardiovascular.
Abstract: Epoxide hydrolase (EH) is a crucial enzyme responsible for catabolism, detoxification,
and regulation of signaling molecules in various organisms including human beings. In mammals,
EHs are classified according to their DNA sequence, sub-cellular location, and activity into eight
major classes: soluble EH (sEH), microsomal EH (mEH), leukotriene A4 hydrolase (LTA4H),
cholesterol EH (ChEH), hepoxilin EH, paternally expressed gene 1 (peg1/MEST), EH3, and EH4.
The sEH, an α/β-hydrolase fold family enzyme, is an emerging pharmacological target in multiple
diseases namely, cardiovascular disease, neurodegenerative disease, chronic pain, fibrosis, diabetes,
pulmonary diseases, and immunological disease. It exhibits prominent physiological effects
including anti-inflammatory, anti-migratory, and vasodilatory effects. Its efficacy has been documented
in various clinical trials and observational studies. This review specifically highlights the
development of soluble epoxide hydrolase inhibitors (sEHIs) in the clinical setting for the management
of metabolic syndrome and related disorders, such as cardiovascular effects, endothelial dysfunction,
arterial disease, hypertension, diabetes, obesity, heart failure, and dyslipidemia. In addition,
limitations and future aspects of sEHIs have also been highlighted which will help the investigators
to bring the sEHI to the clinics.
